LEVISONICS, INC.

Medtech · Private

Acoustic tweezing platform for comprehensive blood coagulation testing from a single drop of whole blood

Grants
$1.7M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Innovative Platform for Low Volume Blood Coagulation Analysis$225,000
Federal grantDepartment of Health and Human Services · Phase I · Drop-of-blood technology for home-use monitoring of anticoagulant therapy$225,177
Federal grantNational Science Foundation · Phase II · SBIR Phase II: Innovative Platform for Low Volume Blood Coagulation Analysis$998,857
Federal grantDepartment of Health and Human Services · Phase I · Coagulation Monitoring in Hemophilia via Acoustic Tweezing Spectroscopy$299,309
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1409Renata Medical, Inc.—$16M
1410BIRED IMAGING INC——
1411LINUS HEALTH, INC.—$54M
1412LEVISONICS, INC.——
1413RETROCAUSAL, INC.—$5.3M
1414PHAGE DIAGNOSTICS, INC.——
1415StataDx, Inc.—$6.4M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Containment Cartridges, Apparatuses, and Methods for Acoustic Levitationapplication
  • Containment Cartridges, Apparatuses, And Methods For Acoustic Levitationapplication
  • Containment Cartridges, Apparatuses, And Methods For Acoustic Levitationapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.